| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7056886 | NPS PHARMS INC | GLP-2 formulations |
Sep, 2022
(1 year, 12 days ago) | |
|
US7056886 (Pediatric) | NPS PHARMS INC | GLP-2 formulations |
Mar, 2023
(6 months ago) | |
| US9539310 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9974835 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9555079 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9987334 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9060992 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9981016 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9968656 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9987335 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9592274 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9974837 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9981014 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US7847061 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9545434 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9968655 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9572867 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9993528 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9968658 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9545435 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9592273 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
|
US9555079 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US7847061 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9060992 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9592274 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9592273 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9572867 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9987335 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9993528 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9981016 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9968658 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9974837 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9968656 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9968655 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9987334 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9981014 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9539310 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9545435 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9545434 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9974835 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
Gattex Kit is owned by Nps Pharms Inc.
Gattex Kit contains Teduglutide Recombinant.
Gattex Kit has a total of 40 drug patents out of which 2 drug patents have expired.
Expired drug patents of Gattex Kit are:
- US7056886
- US7056886*PED
Gattex Kit was authorised for market use on 21 December, 2012.
Gattex Kit is available in powder;subcutaneous dosage forms.
Gattex Kit can be used as treatment of adult patients with short bowel syndrome who are dependent on parenteral support.
The generics of Gattex Kit are possible to be released after 16 May, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 16, 2026 |
Drugs and Companies using TEDUGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support
Dosage: POWDER;SUBCUTANEOUS
GATTEX KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic